Product
Insulin degludec
Aliases
Tresiba
13 clinical trials
10 indications
Indication
Diabetes MellitusIndication
Type 2Indication
Type 1Indication
HealthyIndication
Type 2 Diabetes MellitusIndication
Healthy Control ParticipantsIndication
DiabetesIndication
Type 1 Diabetes MellitusIndication
Renal ImpairmentIndication
Type 2 DiabetesClinical trial
Pharmacodynamic Properties of Insulin Icodec During Exercise and Prolonged Fasting in Participants With Type 2 DiabetesStatus: Recruiting, Estimated PCD: 2024-11-04
Clinical trial
Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With DiabetesStatus: Completed, Estimated PCD: 2022-07-05
Clinical trial
A Single and Multiple-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes MellitusStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Multi-centre Prospective Non-interventional Clinical Investigation Studying the Glycaemic Control in Patients With Type 1 Diabetes When Introducing a NovoPen® 6 for Treatment With Tresiba® (Insulin Degludec) & Fiasp® (Fast-acting Insulin Aspart) in a Real-world SettingStatus: , Estimated PCD: 2024-09-05
Clinical trial
A Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control Associated With the Use of Dose Check App and Insulin Degludec in Patients With Type 2 Diabetes Mellitus in Saudi Arabia Under Real-world SettingStatus: , Estimated PCD: 2025-01-27
Clinical trial
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Healthy Subjects and in Subjects With Type 1 DiabetesStatus: Completed, Estimated PCD: 2021-06-23
Clinical trial
A 26-week Trial Comparing the Effect and Safety of Once Weekly Insulin Icodec and Once Daily Insulin Degludec, Both With or Without Non-insulin Anti-diabetic Drugs, in Subjects With Type 2 Diabetes Treated With Basal InsulinStatus: Completed, Estimated PCD: 2022-01-27
Clinical trial
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)Status: Completed, Estimated PCD: 2019-06-14
Clinical trial
A Trial Comparing the Effect and Safety of Insulin Degludec Versus Insulin Detemir, Both in Combination With Insulin Aspart, in the Treatment of Pregnant Women With Type 1 DiabetesStatus: Completed, Estimated PCD: 2020-12-17
Clinical trial
A 12-week Randomized, Controlled Trial to Compare TOUJEO® and TRESIBA® in Terms of Glucose Values in Target Range and Variability During Continuous Glucose Monitoring in Patients With Type 1 Diabetes MellitusStatus: Completed, Estimated PCD: 2021-09-16
Clinical trial
A 24-Week, Multicenter, Randomized, Open-Label, Parallel-Group Trial Comparing the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment: TRENT TrialStatus: Terminated, Estimated PCD: 2023-07-28
Clinical trial
A 26-week Double Blinded, Multiregional, Trial Comparing the Effect and Safety of Once Weekly Insulin Icodec and Once Daily Insulin Degludec 100 Units/mL, Both in Combination With Non-insulin Anti-diabetic Drugs, in Insulin naïve Subjects With Type 2 Diabetes.Status: Completed, Estimated PCD: 2022-06-23
Clinical trial
Pharmacokinetics, Pharmacodynamic, Safety and Immunogenicity Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection ( Tresiba®）in Healthy Subjects: a Phase I Single-center, Randomized, Open-label, Single-dose, Cross-over Clinical StudyStatus: Completed, Estimated PCD: 2022-03-21